Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. World J Gastroenterol 2013; 19(14): 2154-2161 [PMID: 23599641 DOI: 10.3748/wjg.v19.i14.2154]
Corresponding Author of This Article
Fatih Selcukbiricik, MD, Medical Oncology, Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Cerrahpasa, 34300 Istanbul, Turkey. fsbiricik@yahoo.com
Research Domain of This Article
Oncology
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 4 Time to first progression and time to 2nd progression according to treatment (chemotherapy or supportive) care in patients with metastatic gastric cancer (P < 0.001)
Therapeutic approach
n
Average (mo)
Standard deviation
Minimum (mo)
Maximum (mo)
First series of chemotherapy and time to progression
DCF
152
6.56
2.869
1
18
ECF
77
4.56
9.021
1
48
CF
121
4.15
5.546
1
39
Supportive
112
3.85
9.951
2
60
Others
38
5.24
11.954
1
60
Second series of chemotherapy and time to progression
DCF
31
4.38
3.921
2
15
ECF
14
3.71
2.443
2
10
CF
19
3.76
3.914
3
18
Supportive
267
3.39
1.871
1
12
Others
17
3.75
1.528
1
7
Table 5 Comparison of treatment approaches in the first and second series of treatments in metastatic gastric cancer patients
1st-series treatment approach
P value
2nd-series treatment approach
P value
DCF vs 5-FU-LV
0.043
DCF vs ECF
0.050
DCF vs others
0.010
DCF vs Supportive
0.042
DCF vs Supportive
< 0.001
Supportive vs ECF
0.500
DCF vs ECF
< 0.001
DCF vs others
0.605
DCF vs CF
0.480
Irinotecan/Cisp vs ECF
0.423
ECF vs CF
0.960
Supportive vs Irinotecan/Cisp
0.100
Supportive vs ECF
< 0.01
DCF vs Irinotecan/Cisp
0.672
Citation: Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. World J Gastroenterol 2013; 19(14): 2154-2161